Does the evidence support pertussis vaccination for adults with chronic respiratory disease?
What the research says:
Among patients with chronic respiratory disease (CRD) pertussis infection can result in severe complications including potentially life-threatening exacerbations. The effectiveness of pertussis vaccination in preventing pertussis infection in adults, including those with CRD, is well established (Van den Steen et al 2022; Zerbo et al 2022). A pertussis-containing Diptheria, Tetanus, Pertusis (DTAP) booster vaccine for adults is available although not routinely offered in all countries. In 2019, 18 of 42 European countries included pertussis as part of their vaccine program for adults (Cassimos et al 2020). In the US, pertussis booster vaccination is recommended for all adults not previously adequately vaccinated, although uptake rates are low (American Lung Association 2022).
We suggest based on other recommendations (e.g. GOLD 2023) to ensure patients are sufficiently protected by all relevant vaccines. These might include:
- Single course of a pertussis-containing vaccination for those people not previously adequately vaccinated followed by a booster vaccination every 10 years
- Annual vaccinations for influenza and COVID-19
- Pneumococcal vaccination
- Single course of a shingles vaccination, although in many countries shingles vaccinations are not paid for under national vaccination programmes
What this means for your clinical practice:
- Ensure all those with CRD not previously adequately vaccinated receive a DTAP vaccination
- Consider pertussis-containing booster vaccinations every 10 years for all eligible patients, especially those at highest risk such as adults with CRD
- Chronic Respiratory Disease